P53 expression in patients with advanced urothelial cancer of the urinary bladder

Shahrokh F. Shariat, Christian Bolenz, Pierre I. Karakiewicz, Yves Fradet, Raheela Ashfaq, Patrick J. Bastian, Matthew E. Nielsen, Umberto Capitanio, Claudio Jeldres, Jérôme Rigaud, Stefan C. Müller, Seth P. Lerner, Francesco Montorsi, Arthur I Sagalowsky, Richard J. Cote, Yair Lotan

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Study Type - Prognosis (inception cohort) Level of Evidence 1b Objective To test whether assessing p53 expression could improve the ability to predict disease recurrence and disease-specific survival in a multi-institutional cohort of patients with advanced urothelial carcinoma of the urinary bladder (UCB). Patients and Methods The study comprised 692 patients with pT3-4 N0 or pTany N+ UCB treated with radical cystectomy and lymphadenectomy. The predictive accuracy (PA) was quantified using the 200 bootstrap-corrected concordance index. The base model comprised age, gender, stage, grade, lymphovascular invasion, number of lymph nodes removed, number of lymph nodes positive, concomitant carcinoma in situ, and adjuvant chemotherapy. Results p53 expression was altered in 341 (49.3%) patients. In multivariable analyses, p53 expression was independently associated with disease recurrence (hazard ratio, 1.66; P < 0.001) and cancer-specific mortality (hazard ratio 1.65, P < 0.001). Overall, adding p53 did not significantly improve the PA of the base model (recurrence +0.7%, P = 0.085, and cancer-specific mortality +1.2%, P = 0.050). In the subgroups of pT3N0 (280) and pT4N0 (83) patients, p53 slightly improved the PA of the base model by a statistically significant degree (recurrence +1.7% and +3.6%, respectively; cancer-specific mortality +1.9% and +3.5%, respectively; all P < 0.001). In 329 patients with pTany N+ disease p53 status did not improve the PA of the base model. Conclusion While assessing p53 expression has limited utility in patients with lymph node-positive UCB, it marginally improves prognostication in patients with advanced non-metastatic UCB. Integration of p53 into a panel of biomarkers might be necessary to capture a more accurate picture of the biological potential of advanced UCB.

Original languageEnglish (US)
Pages (from-to)489-495
Number of pages7
JournalBJU International
Volume105
Issue number4
DOIs
StatePublished - Feb 2010

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Carcinoma
Recurrence
Lymph Nodes
Mortality
Neoplasms
Cystectomy
Carcinoma in Situ
Adjuvant Chemotherapy
Lymph Node Excision
Biomarkers
Survival

Keywords

  • Bladder cancer
  • Immunohistochemistry
  • Lymph node metastasis
  • P53
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Urology

Cite this

Shariat, S. F., Bolenz, C., Karakiewicz, P. I., Fradet, Y., Ashfaq, R., Bastian, P. J., ... Lotan, Y. (2010). P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU International, 105(4), 489-495. https://doi.org/10.1111/j.1464-410X.2009.08742.x

P53 expression in patients with advanced urothelial cancer of the urinary bladder. / Shariat, Shahrokh F.; Bolenz, Christian; Karakiewicz, Pierre I.; Fradet, Yves; Ashfaq, Raheela; Bastian, Patrick J.; Nielsen, Matthew E.; Capitanio, Umberto; Jeldres, Claudio; Rigaud, Jérôme; Müller, Stefan C.; Lerner, Seth P.; Montorsi, Francesco; Sagalowsky, Arthur I; Cote, Richard J.; Lotan, Yair.

In: BJU International, Vol. 105, No. 4, 02.2010, p. 489-495.

Research output: Contribution to journalArticle

Shariat, SF, Bolenz, C, Karakiewicz, PI, Fradet, Y, Ashfaq, R, Bastian, PJ, Nielsen, ME, Capitanio, U, Jeldres, C, Rigaud, J, Müller, SC, Lerner, SP, Montorsi, F, Sagalowsky, AI, Cote, RJ & Lotan, Y 2010, 'P53 expression in patients with advanced urothelial cancer of the urinary bladder', BJU International, vol. 105, no. 4, pp. 489-495. https://doi.org/10.1111/j.1464-410X.2009.08742.x
Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU International. 2010 Feb;105(4):489-495. https://doi.org/10.1111/j.1464-410X.2009.08742.x
Shariat, Shahrokh F. ; Bolenz, Christian ; Karakiewicz, Pierre I. ; Fradet, Yves ; Ashfaq, Raheela ; Bastian, Patrick J. ; Nielsen, Matthew E. ; Capitanio, Umberto ; Jeldres, Claudio ; Rigaud, Jérôme ; Müller, Stefan C. ; Lerner, Seth P. ; Montorsi, Francesco ; Sagalowsky, Arthur I ; Cote, Richard J. ; Lotan, Yair. / P53 expression in patients with advanced urothelial cancer of the urinary bladder. In: BJU International. 2010 ; Vol. 105, No. 4. pp. 489-495.
@article{85cc8b94e3f348328bc34395c90a41d5,
title = "P53 expression in patients with advanced urothelial cancer of the urinary bladder",
abstract = "Study Type - Prognosis (inception cohort) Level of Evidence 1b Objective To test whether assessing p53 expression could improve the ability to predict disease recurrence and disease-specific survival in a multi-institutional cohort of patients with advanced urothelial carcinoma of the urinary bladder (UCB). Patients and Methods The study comprised 692 patients with pT3-4 N0 or pTany N+ UCB treated with radical cystectomy and lymphadenectomy. The predictive accuracy (PA) was quantified using the 200 bootstrap-corrected concordance index. The base model comprised age, gender, stage, grade, lymphovascular invasion, number of lymph nodes removed, number of lymph nodes positive, concomitant carcinoma in situ, and adjuvant chemotherapy. Results p53 expression was altered in 341 (49.3{\%}) patients. In multivariable analyses, p53 expression was independently associated with disease recurrence (hazard ratio, 1.66; P < 0.001) and cancer-specific mortality (hazard ratio 1.65, P < 0.001). Overall, adding p53 did not significantly improve the PA of the base model (recurrence +0.7{\%}, P = 0.085, and cancer-specific mortality +1.2{\%}, P = 0.050). In the subgroups of pT3N0 (280) and pT4N0 (83) patients, p53 slightly improved the PA of the base model by a statistically significant degree (recurrence +1.7{\%} and +3.6{\%}, respectively; cancer-specific mortality +1.9{\%} and +3.5{\%}, respectively; all P < 0.001). In 329 patients with pTany N+ disease p53 status did not improve the PA of the base model. Conclusion While assessing p53 expression has limited utility in patients with lymph node-positive UCB, it marginally improves prognostication in patients with advanced non-metastatic UCB. Integration of p53 into a panel of biomarkers might be necessary to capture a more accurate picture of the biological potential of advanced UCB.",
keywords = "Bladder cancer, Immunohistochemistry, Lymph node metastasis, P53, Recurrence, Survival",
author = "Shariat, {Shahrokh F.} and Christian Bolenz and Karakiewicz, {Pierre I.} and Yves Fradet and Raheela Ashfaq and Bastian, {Patrick J.} and Nielsen, {Matthew E.} and Umberto Capitanio and Claudio Jeldres and J{\'e}r{\^o}me Rigaud and M{\"u}ller, {Stefan C.} and Lerner, {Seth P.} and Francesco Montorsi and Sagalowsky, {Arthur I} and Cote, {Richard J.} and Yair Lotan",
year = "2010",
month = "2",
doi = "10.1111/j.1464-410X.2009.08742.x",
language = "English (US)",
volume = "105",
pages = "489--495",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - P53 expression in patients with advanced urothelial cancer of the urinary bladder

AU - Shariat, Shahrokh F.

AU - Bolenz, Christian

AU - Karakiewicz, Pierre I.

AU - Fradet, Yves

AU - Ashfaq, Raheela

AU - Bastian, Patrick J.

AU - Nielsen, Matthew E.

AU - Capitanio, Umberto

AU - Jeldres, Claudio

AU - Rigaud, Jérôme

AU - Müller, Stefan C.

AU - Lerner, Seth P.

AU - Montorsi, Francesco

AU - Sagalowsky, Arthur I

AU - Cote, Richard J.

AU - Lotan, Yair

PY - 2010/2

Y1 - 2010/2

N2 - Study Type - Prognosis (inception cohort) Level of Evidence 1b Objective To test whether assessing p53 expression could improve the ability to predict disease recurrence and disease-specific survival in a multi-institutional cohort of patients with advanced urothelial carcinoma of the urinary bladder (UCB). Patients and Methods The study comprised 692 patients with pT3-4 N0 or pTany N+ UCB treated with radical cystectomy and lymphadenectomy. The predictive accuracy (PA) was quantified using the 200 bootstrap-corrected concordance index. The base model comprised age, gender, stage, grade, lymphovascular invasion, number of lymph nodes removed, number of lymph nodes positive, concomitant carcinoma in situ, and adjuvant chemotherapy. Results p53 expression was altered in 341 (49.3%) patients. In multivariable analyses, p53 expression was independently associated with disease recurrence (hazard ratio, 1.66; P < 0.001) and cancer-specific mortality (hazard ratio 1.65, P < 0.001). Overall, adding p53 did not significantly improve the PA of the base model (recurrence +0.7%, P = 0.085, and cancer-specific mortality +1.2%, P = 0.050). In the subgroups of pT3N0 (280) and pT4N0 (83) patients, p53 slightly improved the PA of the base model by a statistically significant degree (recurrence +1.7% and +3.6%, respectively; cancer-specific mortality +1.9% and +3.5%, respectively; all P < 0.001). In 329 patients with pTany N+ disease p53 status did not improve the PA of the base model. Conclusion While assessing p53 expression has limited utility in patients with lymph node-positive UCB, it marginally improves prognostication in patients with advanced non-metastatic UCB. Integration of p53 into a panel of biomarkers might be necessary to capture a more accurate picture of the biological potential of advanced UCB.

AB - Study Type - Prognosis (inception cohort) Level of Evidence 1b Objective To test whether assessing p53 expression could improve the ability to predict disease recurrence and disease-specific survival in a multi-institutional cohort of patients with advanced urothelial carcinoma of the urinary bladder (UCB). Patients and Methods The study comprised 692 patients with pT3-4 N0 or pTany N+ UCB treated with radical cystectomy and lymphadenectomy. The predictive accuracy (PA) was quantified using the 200 bootstrap-corrected concordance index. The base model comprised age, gender, stage, grade, lymphovascular invasion, number of lymph nodes removed, number of lymph nodes positive, concomitant carcinoma in situ, and adjuvant chemotherapy. Results p53 expression was altered in 341 (49.3%) patients. In multivariable analyses, p53 expression was independently associated with disease recurrence (hazard ratio, 1.66; P < 0.001) and cancer-specific mortality (hazard ratio 1.65, P < 0.001). Overall, adding p53 did not significantly improve the PA of the base model (recurrence +0.7%, P = 0.085, and cancer-specific mortality +1.2%, P = 0.050). In the subgroups of pT3N0 (280) and pT4N0 (83) patients, p53 slightly improved the PA of the base model by a statistically significant degree (recurrence +1.7% and +3.6%, respectively; cancer-specific mortality +1.9% and +3.5%, respectively; all P < 0.001). In 329 patients with pTany N+ disease p53 status did not improve the PA of the base model. Conclusion While assessing p53 expression has limited utility in patients with lymph node-positive UCB, it marginally improves prognostication in patients with advanced non-metastatic UCB. Integration of p53 into a panel of biomarkers might be necessary to capture a more accurate picture of the biological potential of advanced UCB.

KW - Bladder cancer

KW - Immunohistochemistry

KW - Lymph node metastasis

KW - P53

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=76149145040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149145040&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08742.x

DO - 10.1111/j.1464-410X.2009.08742.x

M3 - Article

C2 - 19659466

AN - SCOPUS:76149145040

VL - 105

SP - 489

EP - 495

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 4

ER -